Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Comprehensive Review of Drug–Drug Interactions with Metformin

A Comprehensive Review of Drug–Drug Interactions with Metformin Metformin is the world’s most commonly used oral glucose-lowering drug for type 2 diabetes, and this is mainly because it protects against diabetes-related mortality and all-cause mortality. Although it is an old drug, its mechanism of action has not yet been clarified and its pharmacokinetic pathway is still not fully understood. There is considerable inter-individual variability in the response to metformin, and this has led to many drug–drug interaction (DDI) studies of metformin. In this review, we describe both in vitro and human interaction studies of metformin both as a victim and as a perpetrator. We also clarify the importance of including pharmacodynamic end points in DDI studies of metformin and taking pharmacogenetic variation into account when performing these studies to avoid hidden pitfalls in the interpretation of DDIs with metformin. This evaluation of the literature has revealed holes in our knowledge and given clues as to where future DDI studies should be focused and performed. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Pharmacokinetics Springer Journals

A Comprehensive Review of Drug–Drug Interactions with Metformin

Loading next page...
 
/lp/springer-journals/a-comprehensive-review-of-drug-drug-interactions-with-metformin-NaL6EUTeTk

References (107)

Publisher
Springer Journals
Copyright
Copyright © 2015 by Springer International Publishing Switzerland
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
0312-5963
eISSN
1179-1926
DOI
10.1007/s40262-015-0270-6
pmid
25943187
Publisher site
See Article on Publisher Site

Abstract

Metformin is the world’s most commonly used oral glucose-lowering drug for type 2 diabetes, and this is mainly because it protects against diabetes-related mortality and all-cause mortality. Although it is an old drug, its mechanism of action has not yet been clarified and its pharmacokinetic pathway is still not fully understood. There is considerable inter-individual variability in the response to metformin, and this has led to many drug–drug interaction (DDI) studies of metformin. In this review, we describe both in vitro and human interaction studies of metformin both as a victim and as a perpetrator. We also clarify the importance of including pharmacodynamic end points in DDI studies of metformin and taking pharmacogenetic variation into account when performing these studies to avoid hidden pitfalls in the interpretation of DDIs with metformin. This evaluation of the literature has revealed holes in our knowledge and given clues as to where future DDI studies should be focused and performed.

Journal

Clinical PharmacokineticsSpringer Journals

Published: May 6, 2015

There are no references for this article.